Abbott Diabetes care
- Company typePublic
- Founded1888
- HeadquartersAlameda, United States
- Headcount501–1,000
- GTM typeB2C
- OfferingHardware or Manufacturing
Abbott Diabetes care firmographics
Firmographics- Name
- Abbott Diabetes care
- Legal name
- Abbott Laboratories
- Website
- https://diabetescare.abbott
- Company type
- Public
- Founded year
- 1888
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Abbott Diabetes care industry classification
Industry- Product category
- Continuous Glucose Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industries
- Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
Keywords
Where Abbott Diabetes care is headquartered
LocationHeadquarters
- HQ city
- Alameda
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Abbott Diabetes care business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- CGM Sensor Sales: Abbott generates primary revenue through the sale of disposable CGM sensors that require replacement every 10-15 days. The recurring sensor purchase model creates a subscription-like revenue stream from the installed user base of 7 million worldwide users.
- Reader and Reader Accessories: Sale of FreeStyle Libre reader devices and compatible accessories for users who prefer dedicated hardware over smartphone apps.
- Software and Cloud Services: Revenue from LibreView cloud-based software platform and LibreLinkUp companion app services that support the CGM ecosystem.
- Technology Licensing: Licensing of FreeStyle Libre CGM technology to insulin pump manufacturers for integration with automated insulin delivery systems, including Medtronic partnership estimated to add $100+ million in annual growth.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Abbott Diabetes care product offering
Product offeringCore offering
Abbott Diabetes Care designs, manufactures, and sells the FreeStyle Libre portfolio of factory-calibrated continuous glucose monitoring (CGM) sensor systems and readers, along with the LibreView cloud software, LibreLinkUp and FreeStyle LibreLink mobile apps. The CGM sensors are worn for 10–15 days and transmit real-time minute-by-minute glucose readings via Bluetooth to smartphones or dedicated readers, eliminating routine finger pricks. The portfolio also includes specialized sensors (Instinct, Instinct Go) for Medtronic pump integration, the Libre Rio over-the-counter CGM, the Lingo consumer wellness system, and traditional blood glucose monitors.
Product overview
Abbott Diabetes Care offers the FreeStyle Libre portfolio, a comprehensive continuous glucose monitoring (CGM) system portfolio led by FreeStyle Libre 3 as the flagship product. The portfolio includes multiple CGM sensor generations (FreeStyle Libre 3 Plus, FreeStyle Libre 2 Plus, FreeStyle Libre Select, FreeStyle Libre 2, and original FreeStyle Libre), supported by mobile applications (Libre App, FreeStyle LibreLink, LibreLinkUp) and cloud-based data management software (LibreView). The company also provides specialized sensors for insulin pump integration (Instinct, Instinct Go) through partnerships with Medtronic, Omnipod, Tandem, and others, as well as traditional blood glucose monitoring systems and the over-the-counter Libre Rio system. The ecosystem is designed for flexible glucose monitoring with real-time readings, automated insulin delivery integration, and connected health features.
Differentiator
Problem solved
Functional benefit
Brands
- FreeStyle Libre: World-leading continuous glucose monitoring portfolio including FreeStyle Libre, FreeStyle Libre 2, FreeStyle Libre 3, FreeStyle Libre 3 Plus, FreeStyle Libre Select, and Libre Rio systems.
- Lingo
- Instinct
- LibreView
- LibreLinkUp
Products and services
- FreeStyle Libre 3 System Continuous glucose monitoring system delivering 14-15 days of factory-calibrated, real-time minute-by-minute glucose readings via Bluetooth, the smallest and thinnest sensor in the FreeStyle Libre portfolio, with proven A1c reduction and hypoglycemia reduction.
- FreeStyle Libre 3 Plus Sensor CGM sensor variant authorized for integration with major automated insulin delivery systems, including mylife Loop (CamAPS FX, YpsoPump), Omnipod 5, Tandem t:slim X2, Beta Bionics iLet, and Tidepool twiist.
- FreeStyle Libre 2 System Continuous glucose monitoring system proven to help reduce hypoglycemia, with up to 15 days of wear, optional real-time alarms, and excellent accuracy in the low glucose range.
- FreeStyle Libre 2 Plus Sensor CGM sensor variant authorized for use with Omnipod 5 Automated Insulin Delivery System and Tandem t:slim X2 insulin pump.
- FreeStyle Libre Select System 15-day wear CGM sensor system that moves with users through showers, swimming, and exercise, with accurate glucose readings sent to an app or reader every minute.
- FreeStyle Libre System Original flash glucose monitoring system requiring no finger pricks, with a 1-second scan to view CGM data; water-resistant and wearable for up to 14 days.
- Libre App Companion mobile app for the FreeStyle Libre family of sensors featuring automatic glucose updates every minute and an enhanced alerts experience with escalating alarms and silent mode.
- FreeStyle LibreLink App Mobile app for FreeStyle Libre sensor users that displays glucose data and is compatible with NovoPen 6 and NovoPen Echo Plus smart insulin pens.
- LibreView Cloud-based software for glucose data management, integrated with FreeStyle Libre systems for viewing and sharing glucose data with healthcare providers.
- LibreLinkUp App Companion mobile app allowing users to share glucose insights with caregivers and family members, with compatibility for Omnipod 5 cloud connection.
- Libre Rio Continuous Glucose Monitoring System Non-intensive, over-the-counter integrated CGM device FDA-cleared in June 2024 for non-intensive glucose management without a prescription.
- Lingo Glucose Monitoring System Consumer-focused glucose monitoring system available in the U.S. for general wellness and health tracking.
- Instinct Sensor FreeStyle Libre-family sensor authorized for use with the Medtronic MiniMed 780G insulin pump and MiniMed Go Smart MDI app for automated insulin delivery.
- Instinct Go Sensor Sensor variant authorized for use with the MiniMed Go Smart MDI app, designed for simplified insulin delivery management.
- Blood Glucose Monitoring (BGM) Systems Traditional blood glucose monitors including FreeStyle Precision Neo, FreeStyle Lite, and FreeStyle Freedom Lite, which store insulin doses and glucose readings from finger-prick capillary blood samples.
Quantifiable outcome
- Trusted by 7 million users worldwide compared to other leading personal use sensor-based glucose monitoring systems
- +3 more outcomes
Companies that use Abbott Diabetes care
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles4 records
Abbott Diabetes care technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
Feature5 records
Abbott Diabetes care partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- MedtronicflagshipGlobal partnership integrating Abbott's FreeStyle Libre CGM sensors with Medtronic's automated insulin delivery (AID) systems and smart insulin pens. Bank of America analysts estimate the deal could add over $100 million in annual growth to Abbott's Libre franchise and open a $700-850 million CGM market opportunity. Partnership gives Abbott access to Medtronic's 700,000 global insulin pump users, including 300,000 in the U.S.
- mylife Diabetes CarecoreFreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors authorized for use with mylife Loop automated insulin delivery system, including mylife CamAPS FX app and mylife YpsoPump insulin pump. Available in multiple European countries including France, Germany, Italy, Netherlands, Spain, UK.
- Insulet CorporationcoreFreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus sensors authorized for use with Omnipod 5 Automated Insulin Delivery System. Available in 16 countries including Australia, Belgium, Denmark, France, Israel, Italy, Kuwait, Netherlands, Norway, Saudi Arabia, Sweden, UAE, UK, and USA.
- Tandem Diabetes CarecoreFreeStyle Libre 3 Plus sensor authorized for use with Tandem t:slim X2 insulin pump. Available in Finland, Italy, Sweden, Switzerland, USA, and New Zealand.
- Novo NordiskcoreFreeStyle LibreLink app compatible with NovoPen 6 and NovoPen Echo Plus smart insulin pens, enabling integration of glucose data with insulin dosing information. Available in 24 countries including major markets in Europe, Australia, Canada, and Japan.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Abbott Diabetes care competitors and assessment
Company assessmentBroad incumbents
- Roche Diabetes Care: Roche is a broad incumbent in the blood glucose monitoring market (Accu-Chek) and a CGM participant, serving a similar diabetes patient base through pharmacy and prescription channels globally.
- LifeScan (Johnson & Johnson): LifeScan, formerly J&J's diabetes care unit, makes OneTouch blood glucose monitoring systems and is a peer in the BGM category, now under Platinum Equity ownership but competing in the same glucose monitoring channel.
Emerging players
- Senseonics Holdings: Senseonics manufactures Eversense, an implantable long-term CGM with 180-day and 365-day sensor wear, offering a differentiated alternative to Abbott's 14-15 day disposable sensors in the same glucose monitoring category.
- Tandem Diabetes Care: Tandem (t:slim X2) is an AID partner that integrates FreeStyle Libre 3 Plus sensors. Operates in the same insulin delivery + CGM ecosystem with overlapping Type 1 diabetes customer base.
- Insulet Corporation: Insulet (Omnipod 5) is both an AID partner integrating FreeStyle Libre 3 Plus sensors and a peer in the connected diabetes device ecosystem. Comparable through its tubeless patch pump technology and overlapping patient population with CGM users.
- Beta Bionics: Beta Bionics (iLet Bionics Pancreas) is an AID partner that integrates FreeStyle Libre 3 Plus sensors, operating in the same closed-loop insulin delivery ecosystem with overlapping Type 1 diabetes patient base.
- Ypsomed: Ypsomed (mylife Diabetes Care) is both an AID integration partner (mylife Loop with YpsoPump and CamAPS FX) and a peer in the connected diabetes device ecosystem, with overlapping CGM and pump customer base in Europe.
Direct peers
- Medtronic: Medtronic competes directly in CGM with its Guardian Connect system and is simultaneously Abbott's largest AID integration partner (MiniMed 780G uses Instinct/Abbott sensors). Comparable as a medtech peer across the diabetes care value chain.
- Ascensia Diabetes Care: Ascensia (formerly Bayer Diabetes Care) provides Contour blood glucose monitoring systems and is a peer in the BGM category that Abbott also serves with its FreeStyle Precision/Lite/Freedom Lite lines.
- Dexcom: Dexcom is the primary direct competitor to Abbott's FreeStyle Libre in the CGM market, with G7 and Stelo (OTC) sensor systems. Both companies compete head-to-head in continuous glucose monitoring for Type 1 and Type 2 diabetes with similar factory-calibrated, smartphone-connected sensors.
Market position
Weaknesses5 records
Competitive moat6 records
Key highlights7 records
Customer concentration
Abbott Diabetes care social profiles
Digital presenceAbbott Diabetes care financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abbott Diabetes care leadership team
Management profileNumber of profiles
Profiles1 record
Abbott Diabetes care funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abbott Diabetes care M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abbott Diabetes care
What does Abbott Diabetes care do?
Abbott Diabetes Care designs, manufactures, and sells the FreeStyle Libre portfolio of factory-calibrated continuous glucose monitoring (CGM) sensor systems and readers, along with the LibreView cloud software, LibreLinkUp and FreeStyle LibreLink mobile apps. The CGM sensors are worn for 10–15 days and transmit real-time minute-by-minute glucose readings via Bluetooth to smartphones or dedicated readers, eliminating routine finger pricks. The portfolio also includes specialized sensors (Instinct, Instinct Go) for Medtronic pump integration, the Libre Rio over-the-counter CGM, the Lingo consumer wellness system, and traditional blood glucose monitors.
Is Abbott Diabetes care a public or private company?
Abbott Diabetes care is a public company. It is classified as public and is currently operating.
When was Abbott Diabetes care founded?
Abbott Diabetes care was founded in 1888. It employs 501 to 1,000 people.
Where is Abbott Diabetes care based?
Abbott Diabetes care is headquartered in Alameda, United States, in the North America region.
How does Abbott Diabetes care make money?
Four revenue lines are on record. CGM Sensor Sales are the primary driver. The others are reader and Reader Accessories, software and Cloud Services and technology Licensing.
Who are Abbott Diabetes care's main competitors?
Broad incumbents on record are Roche Diabetes Care and LifeScan (Johnson & Johnson). Emerging players are Senseonics Holdings, Tandem Diabetes Care, Insulet Corporation, Beta Bionics and Ypsomed. Direct peers are Medtronic, Ascensia Diabetes Care and Dexcom.
Does Abbott Diabetes care have an API?
No public API is recorded for Abbott Diabetes care.
What industry is Abbott Diabetes care in?
Abbott Diabetes care's product category is Continuous Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHAHAL, Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies). Its NAICS code is 334510 and its SIC code is 3845.